Shots:

• The patient recruitment is completed in P-IIb (SIGLEC) trial of AVD-104 (intravitreal) vs Izervay to treat GA secondary to AMD. Trial includes P-IIa & P-IIb studies, both conducted in the US
• In P-IIa part, AVD-104 was well tolerated without any drug-related ocular or systemic SAEs after 3mos. and showed greater reduction in GA lesion progression, improved hyperautofluorescence outcomes & stabilization in BCVA compared to untreated eyes
• The P-IIb part compares AVD-104 to Izervay for treating GA secondary to AMD in subjects (n=300) with GA lesions (2.5mm² to 17.5mm²) & BCVA ≥20/320. Patients will receive treatment for 12mos., with an optional 12mos. extension. 1EP is the difference in GA growth rate at 12mos. P-IIb 12mos. data is anticipated in H2’25

Ref: Businesswire | Image: Aviceda Therapeutics

Rewlated News:- Iveric Bio Reports 24-Month Results of Izervay (avacincaptad pegol) for Geographic Atrophy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com